Natlie Shalet: a results-driven biopharma strategist

Natalie is the visionary force behind NAS Healthcare Solutions. With a specialised focus on market access, strategic pricing, and commercial growth, she brings a wealth of expertise across multiple therapy areas, with deep experience in rare diseases and oncology.

Natalie has a proven track record of leading complex real-world evidence programs and designing clinical trials that are strategically aligned with global reimbursement requirements. This unique skill set is central to our mission of optimising pricing strategies and ensuring that innovative therapies can successfully reach the patients who need them.

Her background includes conducting meticulous due diligence for acquisition targets, combining strong scientific expertise with sharp commercial insight and financial acumen. This allows her to effectively influence cross-functional teams and drive sustainable business growth from the ground up.

Adept at challenging conventional approaches, Natalie fosters a culture of innovation at NAS Healthcare Solutions, relentlessly pursuing impactful outcomes that deliver value for our clients, partners, and the broader healthcare community.

Find out more about our services and see some example of Natalie’s medical writing and editing in the publications list, below.

Natalie Shalet
Natalie Shalet

Natalie and our network of experts have extensive experience building payer networks and panels, running payer and KOL advisory boards, organising workshops, and carrying out tailored interviews and in-depth research.

Our aim is to help you shape clear, practical market access and pricing strategies that support your commercial goals while making a real difference for patients.

If you’re ready to talk through what you need for your project, get in touch to book a call with Natalie and discuss next steps.

Publications

Pharmacoeconomics 
Defining and Measuring the Affordability of New Medicines: A Systematic Review
Antonanzas, F., Terkola, R., Overton, P. M., Shalet, N., Postma, M. 2017

Value in Health
Health-Related Quality of Life and Treatment Satisfaction Among Patients Receiving Novel Anti-Androgen Therapies for The Treatment Of Metastatic Castrate-Resistant Prostate Cancer
Dearden, L., Shalet, N., Artenie, C., Mills, A., Gater, A., Grant, L., & Jackson, C. 2015

Value in Health
How Can We Improve The Design Of Patient Preference Research In Oncology? A Case Study In Metastatic Castrate Resistant Prostate Cancer
Dearden, L., Eliasson, L., de Freitas, H., Shalet, N., Lloyd, A. 2015

Patient Prefer Adherence
Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic
Review
Overton, P. M., Shalet, N., Somers, F., Allen, J. A. 2021

Appl Health Econ Health Policy
Ethical Hurdles in the Prioritization of Oncology Care
de Groot, F., Capri, S., Castanier, J. C., Cunningham, D., Flamion, B., Flume, M., Herholz, H., Levin, L. A., Sola-Morales, O., Rupprecht, C. J., Shalet, N., Walker, A., Wong, O.  2017

Value in Health
Variation in Health Technology Assessment and Reimbursement Processes in Europe
Akehurst, R.L., Abadie, E., Renaudin, N., Sarkozy, F.  2017

Pharmacoeconomics
The Value of Medicines: A Crucial but Vague Concept
Antonanzas, F., Terkola, R., Postma, M. 2016 (Editorial Support)

Int J Technol Assess Health Care
Defining Innovation with Respect to New Medicines: A Systematic Review from a Payer Perspective
de Sola-Morales, O., Cunningham, D., Flume, M., Overton, P. M., Shalet, N., Capri, S. 2018

Value in Health
A Description Of Real-World Treatment With Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer Patients In The Post-
Chemotherapy Setting In France And The Netherlands
Dearden, L., Musingarimi, P., Shalet, N., Demuth, D., Garcia Alvarez, L., Muthutantri, A.,Venerus, A., Lasry, R., Hankins, M., Maher, T. 2015

Eur J Cancer Care (Engl)
Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the
treatment of metastatic castrate-resistant prostate cancer
Dearden, L., Shalet, N., Artenie, C., Mills, A., Jackson, C., Grant, L., Gater , A. 2019

BMC Health Serv Res
Personalized medicine in Europe: not yet personal enough?
Di Paolo, A., Sarkozy, F., Ryll, B., Siebert, U. 2017

Eur J Health Econ 
Economic evaluation of personalized medicine: a call for real-world data
Terkola, R., Antonanzas, F., Postma, M. 2017 (Editorial Support)

What our clients say

Natalie is the “go-to expert” for any market access issue. She combines insight, honesty and hard work and has a unique way of getting answers to difficult questions from hard-to-reach and hard-to-engage individuals. All in all refreshing and stimulating work.

Mark Duckham, Managing Director, Bray Leino Healthcare

I worked with Natalie as a colleague in pharma custom consulting engagements. She was knowledgeable, very professional and dependable in all the work we did together.

Bob Ramsay, VP and CSP, Kantar Health

I worked with Natalie for some years in IMS Health and found her to be one of the most driven, adaptable and resourceful individuals, She has a ‘can-do’ attitude to everything she undertakes.

Robert Thurston, Client